The Regulation of Cell Size  by Lloyd, Alison C.
Leading Edge
ReviewThe Regulation of Cell Size
Alison C. Lloyd1,*
1MRC Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College London, Gower Street, LondonWC1E 6BT, UK
*Correspondence: alison.lloyd@ucl.ac.uk
http://dx.doi.org/10.1016/j.cell.2013.08.053
An adult animal consists of cells of vastly different size and activity, but the regulation of cell size
remains poorly understood. Recent studies uncovering some of the signaling pathways important
for size/growth control, together with the identification of diseases resulting from aberrations in
these pathways, have renewed interest in this field. This Review will discuss our current under-
standing of how a cell sets its size, how it can adapt its size to a changing environment, and how
these processes are relevant to human disease.Introduction
The adult animal represents an endpoint of sorts, consisting of
the surviving cells from the extensive growth, proliferation, and
remodeling that takes place during development. Many of these
cells continue to proliferate during adulthood, but one trait that
distinguishes most adults from developmental stages is that
the adult aims to remain more or less the same, hence the
term homeostasis. In the adult, homeostatic mechanisms main-
tain cell number and size to preserve organ size and function.
However, this outward appearance of stability belies the com-
plex balance of positive and negative regulatory stimuli required
to maintain tissues with the differing proliferative and metabolic
activities that make up a complex organism.
In unicellular organisms such as yeast, cell growth and prolif-
eration are mostly controlled by the extracellular nutritional
environment, which allows a direct coupling of resources to
cell generation. Inmulticellular organisms, however, growth, pro-
liferation, and survival need to be differentially regulated in
different tissues, so additional levels of control are required.
This is achieved by providing a more or less constant supply of
nutrients systemically (by the bloodstream or its equivalent),
but in addition, there is a requirement by each cell for an instruc-
tive signal to grow, proliferate, and survive. Thus, a combination
of multiple growth, mitogenic, and survival signals with cell-spe-
cific responses provides the diverse signaling required to pro-
duce and maintain a complex adult organism.
Although the signaling pathways and processes regulating cell
proliferation and cell survival pathways have been intensively
studied, until recently, the regulation of cell growth has received
much less attention. Several new lines of investigation have rein-
vigorated this field of study. Studies showing that cells require
extracellular instructive signals to grow, coupled with the identi-
fication of key signaling pathways, have provided tractable sys-
tems for studying how cell growth is regulated. Moreover, the
identification of abnormalities in these pathways in diseases as
diverse as cancer, cardiac hypertrophy and neurodevelopmental
disorders have highlighted the critical importance of the tight
regulation of these pathways and have identified potential new
therapeutic strategies. In this Review, I will discuss our current
understanding of how cells reach, retain, and adapt their size
and how loss of these controls contributes to humanpathologies.1194 Cell 154, September 12, 2013 ª2013 Elsevier Inc.Cell Growth versus Cell Proliferation
Cell growth (mass accumulation) and proliferation (cell division)
are clearly separable processes. A cell can growwithout dividing
(for example, the growth of postmitotic neurons) and proliferate
without growing (for example the cleavage divisions of a fertilized
egg). Both processes require instructive signals, so a mamma-
lian cell sitting in a culture dish surrounded by nutrients will not
enter the cell cycle or add mass in the absence of a mitogen or
growth factor, respectively (Conlon et al., 2001; Rathmell et al.,
2000). These extracellular controls appear to be so stringent
that, in the absence of a growth signal, a cell will ‘‘eat’’ itself
rather than use the external supply of nutrients (Lum et al.,
2005). However, despite both processes being regulated by
extrinsic instructive signals, there are important differences be-
tween growth and proliferation that need to be considered to un-
derstand how they are regulated and coordinated.
Progression through the cell cycle tends to be an all-or-
nothing, unidirectional process triggered by a threshold level of
mitogenic signaling. Thus, although the rate at which cells prog-
ress through the cell cycle can vary, cells are either in the cycle as
a result of mitogen stimulation or out of the cycle either because
mitogen levels are too low or because the cell has permanently
withdrawn from the cycle—for example, in terminally differenti-
ated postmitotic cells. In contrast, most cells, whether in or out
of the cycle—and many are permanently out of cycle for the
entire adult lifespan—are constantly making and degrading
macromolecules to maintain biological functions. The amount
and type of biosynthetic activity can vary dramatically between
cell types (compare rapidly dividing cells, nondividing secretory
cells, metabolically active but postmitotic neurons, and quies-
cent oocytes). Yet, each of these cells is set to make and
degrade macromolecules at a rate suitable for its needs to either
maintain homeostasis or respond to a stimulus. A cell’s size and
growth rate is therefore determined by the balance between the
rates of accumulation of macromolecules (by synthesis and up-
take) and their loss (by degradation and secretion), which can
vary in a graded fashion in response to changing levels of growth
factor signaling.
The notion that seemingly quiescent cells may actually be
highly biosynthetically active was dramatically shown in a recent
study of mammalian fibroblasts in which biosynthetic activity
was compared between fibroblasts removed from the cell cycle
by contact inhibition and rapidly proliferating cells (Lemons
et al., 2010). Remarkably, the contact-inhibited cells continued
to synthesize proteins at the same rate as the proliferating cells,
even though the contact-inhibited cells were apparently produc-
ing much less net mass over a similar period of time. The expla-
nation was that contact-inhibited cells had changed their
metabolism, increasing the amount of protein degradation and
secreting large amounts of extracellular matrix proteins.
Although these findings probably reflect the differing physiolog-
ical roles of dividing and nondividing fibroblasts, they are also a
potent reminder that intuitive assumptions about the biosyn-
thetic rates of different cells may be highly inaccurate and that
nongrowing, nonproliferating cells can be as biogenic as
growing and proliferating cells.
Establishing and Maintaining Cell Size
The size of an adult organism is determined by both intrinsic
developmental programs and by extracellular signals, which
integrate to control cell number and cell size. Differences in an-
imal size are mostly genetically determined and primarily reflect
differences in cell number rather than differences in cell size
(Conlon and Raff, 1999). However, despite the more or less fixed
target size of most organisms, external signals can still impinge
on this genetic program. One clear example of this is the effects
that nutrient levels can have during development. When in
excess, nutrient levels do not appreciably affect maximal organ-
ismal size, but when limited, they can have a dramatic effect. For
example, it has been shown that extreme nutrient deprivation
during development can decrease a fly’s size to 15% of normal
(Edgar, 2006).
Thus, at least in well-nourished adult animals, tissue size tends
to have been set by the balance between the proliferation and
survival rates of stem and progenitor cells that established the
tissue and the timing of when these cells left the cell cycle or
when they reached a homeostatic state. However, this is not al-
ways the case. Pioneering experiments in Drosophila showed
that inhibiting cell division within half a developing wing disc
had little effect on the final size of the wing as the cell-cycle-
arrested cells grew larger (Su and O’Farrell, 1998). Similarly,
whereas pancreatic size is controlled by progenitor cell number,
liver size is not, indicating that the final size of a tissue can be
determined by its total cell mass rather than cell number (Stanger
et al., 2007).
The size of the cells within a tissue will be the ‘‘readout’’ of their
growth and proliferation rates, both during development and in
the adult, which are controlled by intrinsic programs and the
levels of extracellular mitogens and growth factors, as well as
other factors that can impinge on these pathways such as
nutrient levels, mechanical signals—which can act both posi-
tively (such as stretching during periods of growth) and nega-
tively (for example, crowding within a tissue)—and stress
(Conlon and Raff, 1999; Tumaneng et al., 2012a). The lack of a
fixed cell-sizing mechanism and the separable and independent
regulation of cell growth and proliferative pathways have been
demonstrated in multiple cell types and are shown most clearly
by the repeated finding that increasing the growth rate of cells
usually has little effect on cell number but can dramatically in-crease cell size and hence tissue size (Edgar, 2006; Jorgensen
and Tyers, 2004).
On reaching adulthood, tissues and cells mostly maintain their
size. This homeostatic maintenance of form is seen in rapidly re-
newing epithelial tissues, postmitotic cells such as neurons and
muscle, and regenerative cell types such as liver, endothelial,
and Schwann cells, which can maintain their size for years but
retain the capacity to renter the cell cycle, proliferate, and form
new tissue of the appropriate size. The robustness yet flexibility
of the homeostatic state is likely to require robust but responsive
regulatory networks, and defects of these controls will likely
contribute to disease. Remarkably, these regulatory networks
remain poorly understood even in possibly the simplest situation
to consider, which is themaintenance of the size of a nondividing
cell in the adult. As discussed above, a nondividing adult cell that
maintains a constant size is not in the absence of a growth signal
(it would atrophy) or biosynthetically inactive (it would fail to func-
tion) but rather in a balanced state resulting from a defined level
of growth pathway signaling. In this homeostatic state, the rates
of synthesis and degradation ofmacromolecules are balanced to
result in no net change in the mass or volume of the cell. More-
over, the water content of the cell must be controlled, requiring
stringent controls of osmotic pressure (Koivusalo et al., 2009).
This is all the more remarkable when considering the highly dy-
namic nature of most cells and the rapid turnover of many cell
components and organelles, yet this maintenance of cell size
can last a lifetime. An indication of the controls involved and
the importance of growth factors in their regulation were demon-
strated by studies in sensory neurons, which concluded that syn-
thesis and degradative pathways are coupled in order to main-
tain cell size. In these experiments, the neurons were treated
with the neurotrophin NGF (a growth factor for these cells) in
the presence of increasing levels of an inhibitor of protein synthe-
sis. Incredibly, cell size was maintained because of a propor-
tional decrease in the degradative rates of long-lived proteins.
In contrast, in the absence of NGF, the cells shrank (Franklin
and Johnson, 1998). This coupling of protein synthesis and
degradative pathways could be a general mechanism to provide
robust homeostasis in the face of likely fluctuations in growth
factors, nutrient levels, or cellular damage.
Growth Pathways—Controlling the Growth Rate
Where significant progress has been made in recent years is the
identification of many of the key regulatory pathways that control
cell growth. The best-characterized example of which is the IGF/
PI3K/AKT/mTORC1 pathway (Figure 1). This evolutionary
conserved pathway has been shown to be a major regulator of
cell growth and thus a key determinant of cell size; moreover,
artificial activation of this pathway can promote additional
growth in most cell types tested (Edgar, 2006; Laplante and Sa-
batini, 2012; Tumaneng et al., 2012a). IGF is a classic example of
a limiting growth factor that acts both systemically and at local
tissue levels. Overexpression during development results in
larger animals, mainly due to increases in cell size, and overex-
pression in the adult can result in cell hypertrophy. Binding of
IGF to its receptor activates multiple signaling pathways, but
key to regulating cell growth is the activation of the PI3K/AKT/
mTORC1 axis with mTORC1, a central mediator of the signalCell 154, September 12, 2013 ª2013 Elsevier Inc. 1195
Figure 1. Growth Pathways
A highly simplified cartoon outlining the major
known signaling pathways that regulate cell
growth. For more mechanistic details, please see
the following excellent reviews: Laplante and Sa-
batini (2012), van Riggelen et al. (2010), and Yu
and Guan (2013).from the growth factor to biogenic pathways. In addition,
mTORC1 integrates inputs from at least four other major cues
that can affect cell growth—stress, energy status, oxygen, and
amino acid levels—and thus acts as a signaling node at which
energetic and stress signals can modulate growth factor
signaling (Laplante and Sabatini, 2012). For example, in the
absence of amino acids, IGF is unable to activate mTORC1
signaling. Although full amino acid deprivation is unlikely to occur
in vivo, as animals aim to maintain relatively constant levels of
metabolites, nutritional levels are likely to contribute subtly and
have cell-specific roles in signaling through this pathway.
Increased signaling through the mTORC1 pathway promotes
multiple biogenic processes, including nutrient uptake and pro-
tein and lipid biosynthesis, and modulates cellular metabolism
to promote biogenesis; it also inhibits catabolic pathways such
as autophagy (Locasale and Cantley, 2011). Importantly,
mTORC1 activates a potent negative-feedback loop that, via
IRS, acts to negatively regulate signaling by the IGF receptor,
providing an example of how a biogenic pathway can be buff-
ered to contribute to cell size homeostasis.
Recently, however, it has become clear that mTOR is not
required for the growth of some cell types, and these cell types
seem to be those that are spared in response to nutrient depriva-
tion (Cheng et al., 2011). Neuroblasts in developing Drosophila
continue to grow in starvation conditions, whereas other ‘‘lower
priority’’ tissues are growth restricted to various extents. The
growth of these cells is independent of dTOR, yet requires
both PI3K/AKT signaling and activation of the dTOR targets
S6K and 4E-BP, indicating that these growth pathways have
been ‘‘rewired’’ to make them less sensitive to nutrient levels.
Moreover, these cells are also insensitive to decreasing levels
of circulating insulin-like peptides because the receptor tyrosine1196 Cell 154, September 12, 2013 ª2013 Elsevier Inc.kinase ALK is kept active by a ligand ex-
pressed by the surrounding niche (Cheng
et al., 2011).
Another major regulator of biogenic
pathways is the transcription factor
Myc. Myc increases cell growth and cell
size in multiple tissues and organisms,
and this is associated with increased ri-
bosomal RNA (rRNA) levels, nucleolar
size, increased protein biogenesis, and
the metabolic reprogramming required
for cell growth (Grewal et al., 2005; Sau-
cedo and Edgar, 2002; van Riggelen
et al., 2010; Wang et al., 2011). Impor-
tantly, Myc- and PI3K-dependent cell
growth appears to be driven in part by
distinct mechanisms. In Drosophila fatcells, overexpression of PI3K and Myc causes an equivalent in-
crease in cell volume. However, the Myc cells appear more pro-
tein and ribosome dense with an increase in nucleolar volume
compared to the more lipid-rich PI3K-expressing cells (Saucedo
and Edgar, 2002). This indicates that these two growth-promot-
ing pathways differentially activate biogenic pathways, perhaps
reflecting the requirement of cells to ‘‘grow’’ in different ways de-
pending on their function.
TheHippo pathway is also important in the control of tissue/or-
gan size, mainly by regulating proliferation and apoptosis and
thereby cell number (Tumaneng et al., 2012a). A major down-
stream effector of this pathway is the transcriptional coactivator
YAP1, which activates genes that promote proliferation and pro-
tect against apoptosis. Activation of YAP1 in postnatal liver leads
to a massive expansion of the tissue due to an increase in cell
number; if YAP1 is then switched off, the liver returns to normal
size as the excess cells die by apoptosis. Thus, the Hippo
pathway not only controls the production of cells but sustains
a level of mass perhaps by coordinately controlling both the pro-
liferative and survival pathways (Dong et al., 2007). Producing
and sustaining this mass, however, should also require
increased signaling through a biogenic pathway. Perhaps not
surprisingly, recent work in both Drosophila and mammals has
shown crosstalk between the Hippo and mTOR signaling path-
ways (with YAP1 activating mTOR by decreasing PTEN levels)
and Myc, hence providing mechanisms whereby organ size
can be determined andmaintained by the coordinated regulation
of proliferative, survival, and growth pathways (Csibi and Blenis,
2012; Neto-Silva et al., 2010; Tumaneng et al., 2012b).
Although it is clear that these growth pathways are important
in all tissues tested, their roles in the maintenance of cell size
are less clear. For example, some organs, such as liver and
Figure 2. Extracellular Signals that Regu-
late Cell Size
(A) A set level of growth factors can allow cells to
grow to a specific size. One mechanism may be
that, as a cell grows, it ingests and degrades more
growth factor until an equilibrium is achieved be-
tween the level of factor and the size of the cell.
(B) The amount of NGF produced by the target
tissue controls the size of the neurons that inner-
vate the target.
(C) The amount of ligand (green diamond) is pro-
portional to the size of the axon and controls the
growth of the surrounding Schwann cell.
(D) Flow is detected by the primary cilium on kid-
ney epithelial cells and negatively regulates cell
size.muscle, atrophy following inhibition of mTOR. In contrast, inhib-
iting mTOR activity in the adult prostate or in postnatal granule
neurons of the cerebellum has little detectable effect on the
size of these cells over substantial periods of time (Kwon et al.,
2003; Nardella et al., 2009). They are not restrained at a particular
size, however, as each can increase in size in response to a
growth signal, and this growth is mTOR dependent, showing a
differential requirement for mTOR in the growth versus mainte-
nance of cell size. How cell size is maintained in these cells
and how and if the metabolism of the cell is adapted to cope
with the loss of this fundamental signaling pathway remain to
be determined.
Does a Cell ‘‘Know’’ Its Size?
There is little evidence that a cell directly senses or uses some
type of ruler to measure its size. Instead, cell size reflects a ho-
meostatic level of signaling that produces a balance of anabolic
and catabolic processes that maintain the size of both nonprolif-
erating and proliferating cells. Yet, although cell size is mostly
stable and predictable, it can be changed, indicating that a cell
is constantly responsive to signals that establish and maintain
its size. But what are the signals that set and maintain cell
size? Although mostly poorly characterized, there are certain
cell-specific examples that indicate how cell size can be estab-
lished and that illustrate the importance of both systemic signals
and local signals, as would be expected in order to coordinate
the complex tissue architecture found in multicellular organisms.
It is clear that both systemic and locally acting extracellular
growth factors such as IGF1 can control cell size. These factors
are often limiting and/or produced at higher levels during periods
of growth. Therefore, simplemodels can be constructed in which
a certain level of growth factor will set a certain cell size. For
example, as a cell increases in size, the capacity to degradeCell 154, Septhe growth factor may also increase until
the level of growth factor is lowered to a
level that produces a stable cell size
(Figure 2A).
For some neurons, cell size can be
determined by the level of growth factor
produced by the target tissue (Figure 2B).
Postmitotic neurons often extend very
long axons to innervate their targettissue, a growth process stimulated by local neurotrophins and
other signaling molecules that control the guidance of the axon
(Bellon et al., 2010; Chilton, 2006). Upon target innervation, sig-
nals from the target tissue inhibit further axonal extension (Moon
and Birren, 2008), but then the level of growth factors expressed
by the target tissue determines and maintains the size of the
neuron (Fawcett and Keynes, 1990; Purves et al., 1988). This
has been particularly well established for sympathetic neurons
for which the level of NGF in the target tissue sets the size of
the cell. During development, increasing or decreasing NGF
levels can increase or shrink cell size, a mechanism that allows
the neurons to increase in size in a coordinate fashion with the
increasing size of a target tissue as the animal matures
(Figure 2B). Moreover, this quantitative regulation persists in
the adult, as manipulation of the target size or NGF levels in
the adult can still cause corresponding changes in neuronal
size, demonstrating that NGF both determines and maintains
the size of the cell. This size maintenance, although robust, is
also adaptable because, following injury, the neurons can regen-
erate. Cutting the axons results in a separation from the target
tissue, and the resulting loss of the homeostatic NGF signal
causes dendritic retraction and cell body shrinkage. However,
polarized growth is reinitiated in the axon, presumably in
response to locally produced growth signals at the injury site until
reinnervation re-establishes the NGF signal and the neuron is
restored to its original size.
A further example of how heterotypic cell interactions control
cell size is also provided by the peripheral nervous system
(PNS). Schwann cells interact with all neurons in the PNS, but
they only myelinate those with a diameter greater than 1 mm.
This requires the Schwann cell to ‘‘measure’’ the axonal diameter
and make a distinct differentiation decision based on this mea-
surement.Moreover, the ratio betweenaxondiameter andmyelintember 12, 2013 ª2013 Elsevier Inc. 1197
sheath thickness (the g ratio) is fixed at an optimal value that
achieves the most efficient nerve conduction. This means the
larger the axon, the larger the Schwann cell and requires coordi-
nated growth as the axons continue to grow as the animal ma-
tures (Roberts and Lloyd, 2012). The level of a membrane-bound
ligand neuregulin1 (NRG1) type III presented by the axon controls
both whether an axon is myelinated (a threshold response) and
also the thickness of the myelin sheath (a dose-dependent
response). The larger the axon, the more NRG1 type III is ex-
pressed, whereas the responsible receptor (the ErbB2/3 com-
plex) appears to be in excess, so that increasing numbers of
receptors are likely to be activated in response to a larger axon.
The receptor activates both a biogenic pathway (the PI3K/AKT/
mTOR pathway) and a negative-feedback loop (increasing the
levels of the scaffold Dlg1 that act to stabilize PTEN), which are
both important for stabilizing the size of the Schwann cell at a
given level of the NRG1 signal, and provides a model for how a
different level of receptor signaling can result in a new steady-
state size rather than in perpetual growth (Figure 2C).
A rather different type of signal that regulates cell size has
been identified in the kidney (Boehlke et al., 2010). In polycystic
kidneys, the cells lining the tubules are larger than normal. These
genetic diseases are associated with defective cilia, and a num-
ber of other mutations that disrupt primary cilia also result in an
increase in the size of these cells. Fascinatingly, the role of cilia in
this case is not to sense the level of an extracellular factor but to
detect urine flow and transduce this signal to the growth path-
ways. This involves a mechanism by which the kinase Lkb1,
which is localized within the cilium, is activated by flow to in-
crease the activity of AMPK, a negative regulator of the mTOR
pathway (Figure 2D). Thus, increased flow should maintain a
smaller cell size and contribute to efficient flow through the
tubules. This example of how amechanical signal can contribute
to cell size regulation demonstrates the myriad of signals that
need to be considered in understanding how cell size may be
controlled.
Changing the Size of Nondividing Cells
Theoretically, a cell can increase in size by several mechanisms.
The biosynthetic rates can increase, the degradative rates can
decrease, or both rates can change but the ratio between the
synthetic and degradative rates increases. At first thought, it
may seem that the most energetically expedient way for a cell
to growwould be to increase the synthesis rate while decreasing
the degradative rate. However, in the rare cases in which this has
been measured, it does not appear to be the case in that,
following a growth stimulus, both synthesis and degradative
rates of proteins often increase but the synthetic rate increases
more, resulting in a net increase in protein mass (Conlon and
Raff, 2003; Tipton and Wolfe, 1998). One obvious reason why
degradative rates will increase with any increase in synthesis is
because 30% of all polypeptides are rapidly degraded in the
proteosome following synthesis, with this ‘‘molecular triaging’’
representing 75% of all proteosome substrates (Schubert
et al., 2000).
Most nondividing cells don’t significantly change their size
upon reaching adulthood. However, one cell type that can
change dramatically in size in the adult is the muscle cell (myo-1198 Cell 154, September 12, 2013 ª2013 Elsevier Inc.cytes). Following exercise, particularly mechanical-load-incur-
ring exercise, adult muscle will increase in size as a result of in-
dividual cells growing in the absence of proliferation of either the
myocytes themselves or the muscle stem cell population (satel-
lite cells) (Braun and Gautel, 2011). Conversely, in adverse con-
ditions such as starvation, disuse, or wasting pathological
states, individual myocytes atrophy. Althoughmuscle, like all tis-
sues, is highly specialized, studies on the changes in size of this
tissue give clues to how cell size can both bemaintained and can
change during adulthood.
Two major pathways have been shown to be important for
regulating the size of adult skeletal muscle. On the anabolic
side is the IGF/PI3K/AKT/mTORC1 pathway, which controls
multiple biogenic pathways, including protein translation. On
the catabolic side is the myostatin/SMAD2/3 pathway (Otto
and Patel, 2010). Myostatin is a member of the TGFb family, is
secreted by muscle, and is thought to act mostly locally to nega-
tively regulate muscle mass. Mutations in the myostatin gene
have been shown to lead to a massive increase in muscle size
in multiple species; indeed, cows selected for larger muscles
contain mutations in this gene. Much of the effects of myostatin
have been shown to take place during development by nega-
tively regulating the proliferation, differentiation, and growth of
muscle progenitor cells; however, myostatin is still produced in
the adult and inhibition in adult muscle results in hypertrophy,
showing that the pathway continues to inhibit adult muscle
growth (Otto and Patel, 2010; Sartori et al., 2009). Similarly, inhi-
bition of the AKT/mTORC1 pathway in the adult results in muscle
atrophy, whereas activation of the pathway results in hypertro-
phy (Schiaffino et al., 2013). There is negative feedback regula-
tion in both pathways and crosstalk between them, with much
of the ability of myostatin/SMAD2/3 to inhibit cell growth being
dependent on modulation of AKT/mTOR signaling (Figure 3)
(Sartori et al., 2009; Trendelenburg et al., 2009; Winbanks
et al., 2012). The size of adult muscle cells will thus be the result
of a balance between these two pathways, resulting in a synthe-
sis and degradative balance such that there is no net growth.
Following exercise, there is an increase in mTORC1 signaling
that appears to bemostly independent of PI3K/AKT and involves
force/stretch signaling mediated by mechanosensors
embedded in the sarcomere (Bodine et al., 2001b; Miyazaki
and Esser, 2009). In response to this signal, it appears that
both protein synthesis and degradative rates increase, but syn-
thetic rates increase disproportionally, resulting in muscle cell
hypertrophy (Biolo et al., 1995; Tipton and Wolfe, 1998). A new
size is reached, with further increases in size produced following
further bouts of exercise. Interestingly, however, this increase in
mass is not maintained unless the exercise is maintained (note
the gym maxim ‘‘use it or lose it’’), indicating the importance of
continuous signaling through the mTOR pathway to maintain
muscle size.
A further interesting observation is that, following a constitu-
tive increase in signaling through the AKT/mTOR pathway, mus-
cle cells increase in size (as would be expected following an
increase in signaling through biogenic pathways) but do not
continue to grow; rather, they stop at a larger size (Lai et al.,
2004). This requires constant elevated signaling through this
pathway but must also involve negative regulators (a parallel
Figure 3. Regulation of Skeletal Muscle
Size
Simplified cartoon of the main signaling pathways
that maintain and can change the size of skeletal
muscle. Biogenic pathways are shown in blue,
negative regulators are shown in cream, and the
pathways activated during muscle atrophy are
shown in green. Negative-feedback loops of both
pathways are indicated.increase in degradative pathways, for example) that will result in
the maintenance of a larger cell size rather than continuous
growth.
Following starvation and in other pathological states, muscles
can rapidly losemass as a result of an increase in specific degra-
dation pathways, which appear to have a minor role in maintain-
ing normal muscle size. In this situation, proteins are targeted for
degradation by both the ubiquitin-proteosome system and the
lysosomal autophagic pathway. The regulation of the genes
involved in triggering these processes—the so-called atrophy-
related genes—are under the control of the AKT and mTOR
signaling pathways, and these genes are switched on when
the level of activity of the pathways drops below the basal ho-
meostatic signaling level (Bodine et al., 2001b; Castets et al.,
2013; Stitt et al., 2004). In particular, two of these genes, the
ubiquitin ligases astrogin-1 and MuRF1, are regulated by
FOXO3A, a transcription factor negatively regulated by AKT
(Zhao et al., 2007) (Figure 3). Knockout of these genes produces
mice with normal muscle, showing that the genes are not impor-
tant in regulating normal muscle cell size, but themuscle is resis-
tant to multiple signals capable of inducing muscle atrophy
(Bodine et al., 2001a). The atrophy response most likely reflects
a stress pathway by which muscle breakdown can transiently
provide amino acids to the rest of the body; nevertheless,
following refeeding, muscle cells return to their normal size.
Maintaining and Changing the Size of Proliferating Cells
The majority of studies on cell size control have been performed
on rapidly proliferating populations of cells. These include expo-
nentially proliferating populations of yeast cells or mammalian
cancer cells, as well as developmental systems in which there
is rapid cell proliferation such as the imaginal discs of the fly.
These cell systems have evolved to achieve rapid cell growth
and proliferation, and they make tractable systems for address-
ing many important questions about cell size control. It is useful
to bear in mind, however, that in the adult mammal, this type ofCell 154, Sepsustained, exponential proliferation is
very rare. Therefore, these findings may
have limited relevance.
Observations of proliferating cells re-
vealed that cell growth and cell division
appear to be tightly coordinated in that
cells usually double their mass before
each division and, as a result, maintain a
constant mean size over time. Although
this apparent coordination might just
reflect the ‘‘read-out’’ of specific butseparable growth rates and cell-cycle times, theoretical consid-
erations led to the hypothesis of a direct regulatory link between
cell growth and the cell cycle, which came to be known as the
‘‘cell size checkpoint.’’ The theoretical requirement for a prolifer-
ating cell size checkpoint rested upon whether the addition of
mass in an individual cell occurs in a linear or nonlinear manner
(Conlon and Raff, 2003; Mitchison, 2003). Initial experiments in
yeast determined that growth during the cycle is in fact exponen-
tial in that, as a cell gets bigger, it adds mass at an exponentially
greater rate, a finding that is easy to reconcile with an increase in
ribosomes and other biogenic machinery as a cell increases in
size (Elliott and McLaughlin, 1978). However, if growth in an indi-
vidual cell is exponential, it means that, in a population of cells
with a spread of cell sizes, the bigger cells within the population
would addmoremass over time than the smaller cells so that the
size range of the population would increase over time. That this
does not happen led to the suggestion of a process that can act
to limit this divergence in size, and the search for this elusive ‘‘cell
size checkpoint’’ has continued ever since. In contrast, if cells
add mass in a linear fashion, cells would not require a sensing
of size or a checkpoint mechanism to limit a divergence in cell
size, but an equally mysterious mechanism would be needed
to ‘‘measure’’ the addition of the same amount of mass in a
manner that is independent of the size of the cell.
Whether cells grow in a linear, exponential, or other manner
and how cell size may be linked to the cell cycle remains contro-
versial. Recent studies in yeast—in particular, the budding yeast
S. cerevisiae—have re-explored these issues using single-cell
analysis of mother and daughter cells as they transit through
the cell cycle. Mother cells are much larger than daughter cells,
and as daughter cells have been shown to progress through G1
more slowly than mother cells, this led to the notion that they
needed to reach a critical size before passing Start, the decision
point for entry into S phase (Turner et al., 2012). Several findings
are clear from these and some earlier studies: (1) there is not a
critical cell size or ‘‘Sizer’’ that is the trigger for entry throughtember 12, 2013 ª2013 Elsevier Inc. 1199
Start, as the daughter cells pass through at variable sizes (Lord
and Wheals, 1981; Wheals, 1982); (2) there is no correlation be-
tween the size of themother cell and the time to passage through
Start, implying that once over a certain size, a timer mechanism
is employed (Di Talia et al., 2007; Lord andWheals, 1983); and (3)
there is a size-independent mechanism that explains why
daughter cells pass Start more slowly than mother cells—as
daughters still enter Start more slowly than similarly sizedmother
cells—which appears to be due to asymmetric distribution of
transcription factors that negatively regulate the cell cycle (Di Ta-
lia et al., 2007, 2009; Turner et al., 2012). However, there does
appear to be a degree of size correlation between the daughter
cells in the early period of G1 that suggests that the size of
smaller cells is influencing the duration of passage through this
period of the cell cycle. The mechanism is not clear but has
been linked to the levels of the cyclin CLN3, which controls pas-
sage through this early part of the cell cycle. However, although
there does appear to be some correlation with size, the major
cause of the variability in the time to passage this part of the
cell cycle appears to be size independent and instead reflects
transcriptional noise that causes cell-to-cell variability in the
levels of the lowly expressed CLN3 transcript (Di Talia et al.,
2007).
Interestingly, two recent studies in S. pombe, a fission yeast,
identified a direct mechanism that the cell uses to measure cell
size that does directly impinge on the cell cycle (Martin and Ber-
thelot-Grosjean, 2009; Moseley et al., 2009). S. pombe grow in a
lengthwise manner, with mass added to the end or ends to
create an increasingly longer cell as it progresses through the cy-
cle. The localization of a dose-dependent inhibitor (Pom1) of the
G2/M transition at the ends of the cell creates a spatial gradient
whereby the level of the inhibitor decreases in the nucleus as the
cell elongates, thus directly linking the size (length) of the cell to
entry intomitosis.Whether thismechanism is sufficient to control
the size of proliferating cells and whether its use is limited to
small, elongating, rather rigid cells remain to be clarified.
In mammalian cells, some studies have found that cell growth
is linear, with both synthesis and degradation rates apparently
increasing with cell size, providing a possible mechanism for
adding a fixed amount of mass per unit of time, independent of
cell size (Brooks and Shields, 1985; Conlon and Raff, 2003; Hut-
son and Mortimore, 1982). Other studies have found that growth
is not linear and argue for the existence of a size checkpoint,
although the mechanisms have remained unexplained (Dolznig
et al., 2004; Zetterberg and Killander, 1965). Recently, a number
of increasingly sophisticated methods to measure the mass and
volume of individual cells as they progress through the cell cycle
have been used to re-explore this issue (Godin et al., 2010; Kafri
et al., 2013; Mir et al., 2011; Park et al., 2010; Son et al., 2012;
Tzur et al., 2009). These studies have yet to provide a definitive
answer, but they hint at greater complexities than were initially
envisaged. Although not able to demonstrate either simple linear
or exponential growth through the cell cycle, cells seem to in-
crease their growth rate as they progress through the cell cycle;
this increase is most obvious once cells have entered G2,
perhaps because of the doubling of DNA in S phase. Interest-
ingly, there appears to be a slowing of the growth rate as cells
enter S phase, with a greater slowing in larger cells with a faster1200 Cell 154, September 12, 2013 ª2013 Elsevier Inc.growth rate (Goranov et al., 2009; Kafri et al., 2013). This differ-
ential slowing could act as a mechanism to limit cell size vari-
ability, thus limiting the divergence in cell size without the need
for a classical size sensing mechanism or checkpoint. A further
possibility is that the slowdown in growth rate on entering S
phase could reflect energy depletion associated with the sudden
onset of the energetically expensive process of DNA replication,
which might affect faster growing cells preferentially and may
have less of an effect on cells proliferating in a more pedestrian
manner or in more amenable nutrient conditions.
Another important consideration is that, if there is a cell size
checkpoint in yeast and/or mammals cells, it must be adaptable,
i.e., there cannot be a fixed intrinsic determinant that permits or
triggers passage through the cell cycle at a specific cell size. This
is because it is possible to vary the size of cells. For example,
yeast are different sizes in distinct nutrient conditions, and it is
easy to dramatically change the size of proliferating mammalian
cells by simply varying mitogen and growth factor levels (Conlon
et al., 2001; Echave et al., 2007). This variation in size also rules
out a direct readout of growth rate rather than cell size to regulate
entry into the cell cycle, as cells growing at different rates (such
as yeast in rich versus poor medium) should maintain their size
but just have a shorter cell cycle, which is not the case. In multi-
cellular organisms in vivo, this simplemechanism to alter cell size
by responding to changes in levels of extracellular growth factors
andmitogens seems likely to be the predominant mechanism for
controlling the size of proliferating cells in the animal. This mech-
anism is consistent with in vitro studies and multiple genetic
studies in flies and mice. Importantly, it would provide the flexi-
bility to create the complex tissues, filled with cells of a variety
and changing set of sizes, that are found within multicellular
animals.
Minimal and Maximal Cell Sizes
Related to cell size checkpoints are possible minimal and
maximal limits to cell size. There appear to be limits at both ex-
tremes, but whether these constraints can be considered check-
points and what their physiological relevance may be remain
unclear. There is obviously a minimal limit to the size of a cell
that is viable or that can enter the cell cycle, as a cell requires
a minimum set of components to exist. Interestingly, in the
Schwann cell, this lower limit seems surprisingly small in that,
when cultured in the mitogen neuregulin but in the absence of
growth factors, the cells continue to proliferate until they are so
small that they no longer adhere to the dish (P. Echave and
A.C.L., unpublished data; Conlon et al., 2001). However, there
are examples in which very small cells appear to have to grow
to a minimal size before they can enter the cell cycle. B lympho-
cytes, genetically engineered to survive in the absence of sur-
vival factors, shrink to an extremely small size following the
removal of their growth factor, IL3, (which is also a mitogen);
upon readdition of IL3, there is a clear lag, as the cells grow to
a minimal size before entering the cell cycle (Lum et al., 2005).
This in vitro finding mirrors the situation seen in various develop-
mental situations when small cells produced by division in the
absence of growth grow to a minimal size before re-entering
the cell cycle. A clear example of this is seen during neuroblast
development in Drosophila, when, following rapid early divisions
Figure 4. Independent Regulation of Cell
Growth and Cell Proliferationleading to the production of very small cells, there is a lag during
which the cells grow to a larger size before entry into the next
rounds of divisions (O’Farrell, 2004).
Cell can also reach very large sizes. In particular, some ova
can be 1 mm in diameter, whereas nerve cells can be 1.5 m in
length in humans and up to 12 m long in the giant squid. Howev-
er, these very large cells tend to use highly specialized mecha-
nisms to allow them to grow so large. For example, neurons
have specialized intracellular transport systems and use support
cells to gain nourishment away from the cell body. In vivo, it ap-
pears that most cells are not at their maximal size as they can get
bigger following an increase in growth stimulation. In vitro, in the
presence of saturating levels of growth factors, however, cell
size plateaus at a maximal size. Whether this maximal size
merely reflects a new steady-state size in response to the satu-
rating levels of growth factors or whether there are real spatial or
structural limitations remains unclear. It is easy to envisage
numerous possible limitations: a decrease in surface area/vol-
ume ratio as cell size increases could limit nutrient uptake or a
limit to transcription or translation could stop further growth.
Indeed, the saturation of any biogenic pathway could limit cell
size.
A limiting factor that is likely to be important is the ploidy of the
cell. The evidence for cell ploidy affecting cell size and limiting
cell growth is manifold. First, it has been known for decades
that increasing the ploidy of a cell usually, but not always, in-
creases the size of the cell proportionally (Lee et al., 2009). For
example, tetraploid cells are twice the size of diploid cells. This
does not necessarily mean that the size of a cell is limited by
the genome. It could just reflect that doubling the output of
everything from receptors to ribosomes to genes results in a
doubling of cell size. It does, however, show how cell size can
be influenced by output from the genome. More compelling is
the finding that, in many organisms, large cells or very active
cells tend to have undergone endoreduplication, suggesting
that an increase in ploidy is required either to support a larger
cell or to maintain a highly biosynthetically active cell (LeeCell 154, Sepet al., 2009; Umen, 2005). In mammals,
such cells include liver cells, heart muscle
cells, and trophoblasts, and these endor-
eduplication cycles appear to be impor-
tant for function. In both Drosophila and
C. elegans, many cells undergo endore-
duplication to produce extremely large
cells: for example, a whole muscle in
Drosophila can consist of a single endor-
eduplicated cell. Genetic studies show
that endoreduplication is required for
the Drosophila cells to grow so large,
but whether endoreduplication alone is
sufficient to drive growth is not clear
and may vary between tissues. In fly
muscle, it appears not to be sufficient,because although myc induction is sufficient to trigger poly-
ploidy, it is not sufficient to drive substantial cell growth. In
contrast, in the fat body, there is a correlation between myc in-
duction of polyploidy and cell growth, which is more consistent
with an increase in polyploidy driving cell growth but could
also indicate that myc can efficiently drive both processes in
this tissue (Demontis and Perrimon, 2009; Pierce et al., 2004).
Separation of Growth and Proliferative Pathways
The ability to separately regulate the growth and proliferation
pathways provides a simplemechanism to vary cell size and pro-
vides the flexibility needed to produce the great diversity of cell
types found in the vast spectrum of multicellular organisms.
Thus, in organisms as diverse as C. elegans, Drosophila, and
mouse, cell growth and cell proliferation are frequently out of
synchrony. This allows multiple cell divisions to occur without
growth within an embryo isolated from nutrition and then to
grow rapidly once nutrition is established but after the establish-
ment of a basic body plan. Moreover, it is a simple mechanism to
allow the continued growth of complex tissues during the matu-
ration of many organisms (O’Farrell, 2004).
This does not of course mean that the proliferative and growth
pathways cannot or are not frequently coupled. For example, to
produce a large number of identical cells rapidly—for instance
during the clonal expansion of B or T cells following an infec-
tion—it makes sense to couple the pathways (Figure 4). This
need not require a cell-size-sensing mechanism, however, but
only that the signals stimulating the response activate both
growth and division pathways. The easiest way to achieve this
is by the receptor for such a signal being wired to activate both
pathways. This is clearly seen for IL-3, for example, a ligand
that simultaneously activates the proliferative, growth, and sur-
vival pathways in B cells, and is a simple way to produce a large
number of similar cells (Lum et al., 2005). Conversely, however,
other cells need to separate these processes. Schwann cells
are a good example. They migrate along axons and exit the
cell cycle prior to birth. They then growmassively, concentricallytember 12, 2013 ª2013 Elsevier Inc. 1201
Figure 5. Loss of Homeostatic Size Control in the Adult Results in
Disease and Agingwrapping around an axon and forming amyelinating cell. Howev-
er, these myelinating cells are regenerative and can re-enter the
cell cycle at any moment following an injury signal; thus, these
cells are quiescent rather than postmitotic. This behavior re-
quires a clear separation of the growth and proliferative path-
ways to allow growth in a cell that is poised to enter the cell cycle.
The separation of these pathways has been demonstrated
in vitro in that distinct extracellular factors can differentially regu-
late the growth and proliferative pathways. Thus, whereas a
growth factor such as IGF can drive growth but not proliferation,
the Schwann cell mitogen NRG can drive proliferation indepen-
dently of growth (Roberts and Lloyd, 2012).
Disease
The development of a tumor does not only reflect loss of a cell’s
normal proliferative controls but also reflects loss of normal
growth and survival controls that are needed to produce and
maintain the additional cell mass. All themain signaling pathways
that, whenmutated, are known to drive tumorigenesis have been
linked to the regulation of growth control. In particular, the PI3K/
AKT/mTOR pathway is activated inmost tumors, for example, by
activation of upstream regulators such as Ras or by the loss of
negative regulators such as PTEN (Dazert and Hall, 2011). Myc
is activated in many tumors and, recently, the Rb pathway has
also been shown to be an important regulator of cell growth
and, moreover, cooperates with oncogenic Ras/PI3K signaling
to drive sustained growth (Collins et al., 2012). The realization
of the universal deregulation of growth controls in tumors has
led to the development of new therapeutics, which are based1202 Cell 154, September 12, 2013 ª2013 Elsevier Inc.either on the direct targeting of the growth signaling path-
ways—for example, mTOR inhibitors are now showing promise
in the clinic—or by targeting the metabolic pathways that are
differentially activated in growing cells (Zoncu et al., 2011).
So, whereas cancer involves the loss of both cell growth and
cell proliferation controls—albeit with the additional loss of tissue
boundary controls that can lead to the invasion andmetastasis of
the expanding tumor mass—many other diseases are increas-
ingly thought to involve the overgrowth of nonproliferating tis-
sues. In other words, the deregulation of cell growth controls in
any tissue is likely to result in disease, with too much signaling
resulting in hyperactivity, hypertrophy, or cancer, whereas too
little signaling will result in atrophy (Figure 5). This deregulation
in cell growth controls can be caused by extrinsic or intrinsic
mechanisms. For example, an increase in growth hormone
signaling and hence elevated levels of IGF1 signaling in the adult
result in acromegaly, whereas the deregulated growth seen in
cancer is mostly driven by intrinsic genetic changes.
Cardiac hypertrophy is a major health condition that involves
deregulated growth. It is commonly brought about by a diseased
cardiovascular system promoting a compensatory hypertrophy
of cardiac myocytes that eventually leads to aberrant contractile
function.More surprisingly, perhaps, a number of developmental
brain disorders are likely to be the result of deregulated growth.
This first became clear when the genetic defects involved in a
number of these disorders were identified and shown to be reg-
ulators of growth pathways. These include Lhermitte-Duclos dis-
ease (heterozygous PTEN mutations) and tuberous sclerosis
(heterozygous TSC1 or TSC2 mutations), which both result in
overactivation of the mTOR pathway. These disorders result in
variable intellectual and behavioral disabilities, epilepsy, and
often autism and are associated with a brain ‘‘overgrowth’’ pa-
thology associated with large, dysmorphic neurons, hypertro-
phic astrocytes, and giant cells, as well as defects in synaptic
function (Crino, 2011). In many ways, these abnormal regions
of the brain can be thought of as ‘‘tumors’’ of nondividing
cells—a point reinforced by the observation that some affected
parts of the brain have lost the second tumor suppressor allele
(Kwon et al., 2001). These disorders are considered develop-
mental disorders—brain abnormalities occurring during embryo-
genesis—and they were considered irreversible. Remarkably,
mouse genetic models that mimic the brain disorders both at
the cellular and behavioral level can be largely ‘‘corrected’’ by
treating the animals postnatally with rapamycin, an inhibitor of
mTOR. Not only do these studies provoke rethinking of how
these patients are regarded and might be treated, but they
once more point to the dynamic nature of homeostatic cell size
control. This is further exemplified by the observation that the
mice need to be continually treated, as the cells regrow to their
pathological size following rapamycin withdrawal (Goto et al.,
2011).
Increasingly, defects in growth control and cell size homeosta-
sis are being linked to aging (Zoncu et al., 2011). Although much
of the aging process of an individual species is genetically deter-
mined, organismal lifespan can be modulated by environmental
signals. A good example is the effects of dietary restriction on
lifespan. In organisms as diverse as C. elegans and mouse, a re-
striction of specific components of the diet results in a
substantial increase in the longevity of the organism, at least
partly due to a reduction in IGF signaling (Niccoli and Partridge,
2012). A current view is that increased biogenesis, as a result of
elevated signaling through the IGF/PI3K/AKT/mTORC1
pathway, eventually leads to cellular defects mostly associated
with the accumulation of damaged macromolecules (Bove´
et al., 2011; Zoncu et al., 2011). This has been hypothesized to
result from both an overload of the biosynthetic apparatus—
and an accumulation of improperly processed cell material and
a defect in the degradative machinery—with an inhibition of
cellular autophagy, causing the accumulation of defective
cellular structures and organelles that can contribute to aging-
related disorders such as Alzheimer’s (Figure 5).
A recent fascinating study has also shown how other systemic
signals that regulate cell size can contribute to the aging process
(Loffredo et al., 2013). In mice (and humans), cardiac hypertro-
phy is often observed in older animals. This is associated with
a substantial increase in the size of individual cardiac myocytes,
resulting in an overall increase in the size of the heart. Remark-
ably, parabiotic association (the permanent joining of the blood-
streams) of a young mouse with an old mouse resulted in the
aged heart returning to its youthful size within 4 weeks. The sys-
temic factor was identified as growth differentiation factor 11
(GDF11), a member of the TGFb family, the levels of which
drop precipitously in old animals. Similarly to myostatin in skel-
etal muscle, GDF11 negatively regulates cardiac muscle cell
size, presumably by a similar mechanism. This study further
shows how apparently stable changes in cell size associated
with a pathological disorder can be corrected by re-establishing
the correct balance of signals that normally set the homeostatic
cell size.
Conclusions
The regulation of cell size remains mostly a mysterious process.
Highly dynamic cells can maintain their size for life but can also
grow or shrink, requiring robust but adaptable controls. Cell-
type-specific examples are starting to give clues to the mecha-
nisms that control cell size and highlight the complexity and
diversity of the pathways involved. Moreover, the loss of these
controls can lead to a variety of diseases, emphasizing the
importance of these controls. As technological improvements
in areas such as mass spectrometry and imaging allow us to
measure the dynamic turnover of cellular components with
increasing sensitivity and precision, we can look forward to
exciting new insights in this important field of study.
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